Thank you for your many years of tireless dedication and commitment. Your quest for perfection and honesty is reflected in the financial condition and reporting of Simulations Plus... an example that is rare to find in public companies. The Simulation Plus shareholders give you a very big thank you and hope that your retirement is enjoyable.
What looked like a sales and earnings shortfall has already been booked in Q1. A large order slipped from Q4 into Q1 so we should see continued sales and earnings improvement in the coming reports. There are several new and positive items discussed in the conference call... There have been several cases where SLP software results have been accepted by regulatory agencies and as a result physical drug trials were waived and not required. The drug discovery industry is embracing software solutions and SLP is providing what they need. This is an exciting time to be invested in this industry and SLP has a leadership position. I encourage everyone to listen to the conference call replay that should be available on the SLP web site later today or tomorrow. Also, Seeking Alpha has a conference call transcript.
and closing at the high as well as a new 52 week high. We had a similar day on high volume about 3 weeks ago. It looks like someone wants a lot of shares. The next dividend announcement may surprise a lot of people... Last year at year end a big part of the dividend was paid early so now the current payout looks small. All the financial data that is presented makes it look like the dividend is .03 per quarter when in fact we may actually see 2 X that amount. In reality if SLP continues to pay as they have in the past this is a solid 5% return. In addition I am expecting continued growth in sales and earnings that will keep the share price on an up trend. I am still holding all my shares.
Simulations Plus, Inc. (SLP), a leading provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has completed the molecule design phase of its second NCE (new chemical entity) project, and is issuing requests for quotes to synthesize the new compounds for testing. This second NCE project follows the Company’s successful project that was completed last year to design new molecules to inhibit the malaria parasite.
Dr. Robert Clark, director of life sciences for Simulations Plus, said: “Our target for this second NCE project is cyclooxygenase-2 (COX-2).
A full detailed report is available at Taglich... Sorry but I can't post the information... Yahoo has made it impossible to post information from other sites...
Software Programs Will Help Prioritize Testing for the National Toxicology Program
Simulations Plus, Inc. (SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that it has signed a Material Transfer Agreement (MTA) with the Division of the National Toxicology Program (DNTP) of the U.S. National Institute of Environmental Health Sciences (NIEHS) to provide licenses for its GastroPlus™, ADMET Predictor™, and MedChem Studio™ software programs for use by the DNTP/NIEHS. The DNTP within the NIEHS is conducting research along with several agencies, including the U.S. Environmental Protection Agency, the U.S. Army, the National Human Genome Institute, and the Centers for Disease Control in the National Toxicology Project.